TY  - JOUR
T1  - Susceptibility of Minocycline against Carbapenem Resistant Gram-Negative Bacilli
AU  - Warrier, Anup R
AU  - Babu, Rachana
PY  - 2018
DA  - December
DO  - 10.5799/jmid.493848
JF  - Journal of Microbiology and Infectious Diseases
JO  - J Microbil Infect Dis
PB  - Aydın ECE
WT  - DergiPark
SN  - 2146-3158
SP  - 140
EP  - 146
VL  - 08
IS  - 04
LA  - en
AB  - Objective: Pathogens resistant to ≥3 antimicrobial agents arereferred to multi-drug resistant (MDR) pathogens. Although several antibioticsare available, antibiotics with broader spectrum of activity is required. Thepresent study aimed to evaluate the in vitro susceptibility of minocyclineagainst Carbapenem resistant gram-negative bacilli and its concordancesensitivity as compared to Tigecycline. Methods:Non-repetitive, consecutive isolates carbapenem resistant gram-negative bacilliincluding MDR Klebsiella pneumoniae (K. pneumoniae) and Acinetobacter spp. were used for evaluation using Epsilometer test(E-test). The minimum inhibitory concentration (MIC) cut-off range forminocycline was based on Clinical and Laboratory Standards Institute (CLSI,2016) and the interpretation (sensitive<4, intermediate=8, resistant ≥16)was considered valid for both, Enterobacteriaceaeand Acinetobacter. Concordancesusceptibility of minocycline was compared with that of tigecycline. Results:Overall, 18 isolates from MDR Acinetobacterspp., 20 isolates from MDR Enterspp.obacter spp. (18 E. coli isolates and 2 Enterobacter, undefined), and 63 isolates ofMDR Klebsiella spp. (58 K. pneumoniaeisolates and 5 Klebsiella isolates) were evaluated. In vitro, sensitivity ofminocycline was 50.0% (9/18) in Acinobacter species; 45.0% (9/20) in Enterobacter spp. and 36.5% (23/63) inKlebsiella spp., respectively. Of the 101 isolates used, concordance betweentigecycline and minocycline was observed in 42 isolates (41.6%) and sensitivityto both minocycline and tigecycline was observed in 12 isolates (28.6%). TheCohen Kappa values showed that the overall concordance between tigecycline andminocycline was 0.11 (non-slight agreement).Conclusion: Minocycline is effective against all the threecarbapenem resistant gram-negative bacteria included in the study. J Microbiol Infect Dis 2018; 8(4):140-146.
KW  - Minocycline
KW  - Tigecycline
KW  - sensitivity
KW  - Carbapenem resistant gram-negative bacilli
KW  - in vitro susceptibility
CR  - 1.	Swaminathan AAM, Manoharan A, Nair K P, Girija K R. Characterisation of carbapenemase-producing Gram-negative bacilli among clinical isolates in a tertiary care centre in Kerala, South India. J Acad Clin Microbiol 2016; 18:100-104.
2.	Jean SS, Lee WS, Lam C, Hsu CW, Chen RJ, Hsueh PR. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 2015; 10:407-425.
3.	Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
4.	Basak S, Singh P, Rajurkar M. Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J Pathog 2016; 2016:4065603.
5.	Manchanda V, Sanchaita S, Singh N P. Multidrug resistant Acinetobacter. J Global Infect Dis 2010; 2:291-304. 
6.	Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78:119-146.
7.	Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-821.
8.	Center for Disease Dynamics, Economics & Policy, 2015 Report. The State of the World’s Antibiotics 2015. Available from https://www.cddep.org/wp-content/uploads/2017/06/swa_executive_summary_edits_2016.pdf. Accessed on 19 Dec 2017. 
9.	Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev 2017; 30:409-447.
10.	Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014; 59:S374-S380.
11.	Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014;5:551.
12.	Shankar C, Nabarro LEB, Anandan S, Veeraraghavan B. Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms? Microb Drug Resist 2017; 23:437-446.
13.	Neonakis IK, Spandidos DA, Petinaki E. Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol 2014; 9:299-305.
14.	Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611–614. 
15.	Giammanco A, Calà C, Fasciana T, Dowzicky MJ. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. mSphere. 2017; 2:pii: e00310-e00316.
16.	Microbiology Standards. Clinical & Laboratory Standards Institute (CLSI). Available from: https://clsi.org/standards/products/microbiology/documents/. Accessed on 05 Sep 2018. 
17.	The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. Available from: http://www.eucast.org. Accessed on: 05 Sep 2018. 
18.	E-TEST ( Epsilometer test): Principle, purpose, procedure, results and interpretations. Available from: https://microbeonline.com/e-test-epsilometer-test-principle-purpose-procedure-results-and-interpretations/. Accessed on 02 May 2018. 
19.	van Duin D, Paterson D. Multidrug Resistant Bacteria in the Community: Trends and Lessons Learned. Infect Dis Clin North Am 2016; 30: 377–390.
20.	Giamarellou H, Poulakou G. Multidrug-Resistant Gram-Negative Infections What are the Treatment Options? Drugs 2009; 69: 1879-1901. 
21.	Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis 2010; 51:79-84.
22.	Chen A, Smith KP, Whitfield BA, et al. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagn Microbiol Infect Dis 2017; 88:365-367. 
23.	Dimitriadis P, Protonotariou E, Varlamis S, et al. Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2016; 48:321-323.
24.	Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009; 53:1295-1296.
25.	Goff DA, Kaye KS. Minocycline: An Old Drug for a New Bug: Multidrug-Resistant Acinetobacter baumannii. Clin Infect Dis 2014; 59:S365–S366. 
26.	Veeraraghavan B, Shankar C, Vijayakumar S. Can minocycline be a carbapenem sparing antibiotic? Current evidence. Indian J Med Microbiol. 2016; 34: 513-515. 
27.	Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014; 59:S388-S393.
UR  - https://doi.org/10.5799/jmid.493848
L1  - https://dergipark.org.tr/en/download/article-file/591178
ER  -